Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system

References

• Sills ES, Perloe M, Palermo GD. Correction of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic ovary syndrome: a review of therapeutic rationale and reproductive outcomes. Eur J Obstet Gynecol Reprod Biol 2000; 91:135–41
   Google Scholar
• Zawadzki JK, Dunaif A. Diagnostic criteria for poly-cystic ovary syndrome: towards a rational approach. In Dunaif A, Givens JR, Haseltine F, et al. eds. Polycystic Ovary Syndrome. Boston: Blackwell Scientific Publications, 1992:377–84
   Google Scholar
• Hacihanefioglu B. Polycystic ovary syndrome nomenclature: chaos? Fertil Steril 2000;73:1261–2
   Google Scholar
• Negri M, Shelban I, Arigliano PL, et al. Interrelation between angiographic severity of coronary artery disease and plasma levels of insulin, C-peptide, and plasminogen activator inhibitor-1. Am J Cardio/ 1993; 72:397–401
   PubMedGoogle Scholar
• Lemne C, De Faire U. Elevation of plasminogen activator inhibitor-1 in borderline hypertension is linked to concomitant metabolic disturbances. Eur J Clin Invest 1996;26:692–7
   PubMed Web of Science ®Google Scholar
• Henry M, Tregouet DA, Alessi MC, et al. Metabolic determinants are much more important than genetic polymorphisms in determining the PAT-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arteriosder Thromb Vasc Biol 1998;18:84–91
   PubMed Web of Science ®Google Scholar
• Atiomo WU, Bates SA, Condon JE, et al. The plasminogen activator system in women with poly-cystic ovary syndrome. Fertil Steril 1998;69:236–41
   PubMed Web of Science ®Google Scholar
• Sills ES, Genton MG, Perloe M, et al. Plasma homo-cysteine, fasting insulin, and androgen patterns among women with polycystic ovaries and infertility. J Obstet Gynaecol Res 2001;27:163–8
   PubMed Web of Science ®Google Scholar
• Burchfiel CM, Curb JD, Araki R, et al. Cardiovascular risk factors and hyperinsulinemia in elderly men: the Honolulu Heart Program. Ann Epidemiol 1996;6: 490–7
   Google Scholar
• Kluft C. Criteria and search for specific assays for active plasminogen activator inhibitor 1 (PAI-1) in plasma. J Int Fed Clin Chem Lab Med 2000;12:1–10
   Google Scholar
• Sills ES, Levy DP, Wittkowski KM, et al. Preliminary experience with metformin treatment of polycystic ovary syndrome: reproductive outcomes among 20 consecutive patients. Fertil Steril 1999;72 (Suppl. 1):5187–8
   Google Scholar
• Declerck PJ, Collen D. Measurement of plasmino-gen activator inhibitor (PAT-1) in plasma with various monoclonal antibody-based enyzme-linked immunosorbent assays. Thromb Res 1990;Suppl. X: 3–9
   Google Scholar
• Vaughan D. Update on plasminogen activator-1. Can J Cardio/ 1998;14(Suppl. D) :14D–15D
   Google Scholar
• Leonardsson G, Peng X-R, Liu K, et al. Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators. Proc Nat/ Acad Sci USA 1995;92:12446–50
   Google Scholar
• Estelles A, Grancha S, Gilabert J, et al. Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease. Am J Pathol 1996;149:1229–39
   PubMedGoogle Scholar
• Vesce F, Scapoli C, Giovannini G, et al. Plasminogen activator system in serum and amniotic fluid of euploid and aneuploid pregnancies. Obstet Gynecol 2001;97:404–8
   Google Scholar
• Bellart J, Gilabert R, Fontcuberta J, et al. Coagulation and fibrinolysis parameters in normal parameters and in gestational diabetes. AmJ Perinatol1998;15:479–86
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Phillips H, Cameron D, et al. The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications. Metabolism 2000;49:845–52
   PubMed Web of Science ®Google Scholar
• Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endo-thelial dysfunction. Circulation 2001;103:1410–15
   PubMed Web of Science ®Google Scholar
• Sampson M, Kong C, Patel A, et al. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAT-1) levels in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxj) 1996;45:623–9
   PubMed Web of Science ®Google Scholar
• Abbasi F, McLaughlin T, Lamendola C, et al. Com-parison of plasminogen activator inhibitor-1 concen-tration in insulin-resistant versus insulin-sensitive healthy women. Arteriosder Thromb Vasc Biol 1999;19: 2818–21
   Google Scholar
• Banfi C, Eriksson P, Giandomenico G, et al. Trans-criptional regulation of plasminogen activator inhibi-tor type-1 gene by insulin. Diabetes 2001;50:1522–30
   PubMedGoogle Scholar
• Panahloo A, Yudkin JS. Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease. J Cardiovasc Risk 1997;4:91–9
   PubMedGoogle Scholar
• Nestler JE, Jakubowicz DJ, Evans WS, et al. Effects of metformin on spontaneous and clomiphene-induced ovulation induction in the polycystic ovary syndrome. N Engl J Med 1998;338:1876–80
   PubMed Web of Science ®Google Scholar
• Sills ES, Perloe M, Levy DP, et al. Plasminogen activa-tor inhibitor-1 levels, prothrombin G20210A and methyltetrahydrofolate reductase C677T gene poly-morphism frequencies, and reproductive history: correlations with ultrasonographic ovarian morpho-logy. Fertil Steril 2000;74\(Suppl. 1):S13–14
   Google Scholar